The Bet And The Test (forecast prediction plus its falsifiability)

Here is a bet about where drug discovery goes next, and the one result that could prove it wrong.

The bet: the highest-leverage strategy for common chronic disease is not to find one more disease-specific target, but to build medicines that amplify the body's own systems of wellness and recovery. Metabolism. Inflammation and its resolution. Mitochondrial function. Regeneration. Muscle. These are measurable, druggable control systems, and each one reaches many diseases at once.

We already have proof points. Rapamycin, which acts on the nutrient-sensing hub mTOR, is the only drug shown to extend maximal lifespan in mammals. An anti-inflammatory antibody given to prevent second heart attacks also cut lung cancer incidence in the same trial. And exercise, still the most broadly effective intervention we have, works through exactly these pathways.

The precision comes from combination. Profile which wellness systems are impaired in a given patient, then use an algorithm to select and dose the right combination of levers, and adapt it over time. Same toolkit, different regimen for a diabetic than for a cancer patient in treatment. Now the test. If this is right, wellness levers should help diseases well beyond their original mechanism. If it is wrong, they will help only the disease next door.

In late 2025, the large EVOKE trials asked exactly this: could a GLP-1 drug slow Alzheimer's? The answer was no. It moved some biomarkers but did not slow decline. That is a real warning shot, and I take it seriously. Not every wellness lever reaches every disease.

The strategy has to survive tests like that. I think it will. The trials, not conviction, will decide.

Full argument in comments.

If you are building in this space, what would make you abandon the thesis?